|From: kyleLennon (Rep: 0)||Date: 08/09/2018 00:45|
|Forum: Novavax - Msg #3681||Thread #674026959 (Rec: 0) |
|While Novavax has some positives, it is not a good candidate for new money. Novavax's two marquee programs, RSV F for maternal vaccination and NanoFlu are not doing particularly well, as they are getting delayed. |
RSV F for maternal vaccination is now in Phase 3, but many investors are wondering if it's a viable drug. Even if Novavax successfully meets the development challenges, it may face strong competition from other biotech companies.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.